Principal Financial Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,051
| Closed | -$719K | – | 2484 |
|
|
2023
Q2 | $719K | Sell |
7,051
-941
| -12% | -$89K | ﹤0.01% | 1887 |
|
|
2023
Q1 | $727K | Sell |
7,992
-207
| -3% | -$12.1K | ﹤0.01% | 1904 |
|
|
2022
Q4 | $311K | Buy |
+8,199
| New | +$282K | ﹤0.01% | 2091 |
|
|
2022
Q3 | – | Sell |
-7,371
| Closed | -$224K | – | 2594 |
|
|
2022
Q2 | $224K | Buy |
+7,371
| New | +$220K | ﹤0.01% | 2266 |
|
|
2021
Q4 | – | Sell |
-11,622
| Closed | -$1.17M | – | 2671 |
|
|
2021
Q3 | $1.17M | Buy |
11,622
+221
| +2% | +$25.9K | ﹤0.01% | 1974 |
|
|
2021
Q2 | $1.61M | Buy |
11,401
+2,386
| +26% | +$269K | ﹤0.01% | 1955 |
|
|
2021
Q1 | $899K | Buy |
9,015
+306
| +4% | +$35.7K | ﹤0.01% | 2018 |
|
|
2020
Q4 | $1.08M | Sell |
8,709
-5
| -0.1% | -$657 | ﹤0.01% | 1930 |
|
|
2020
Q3 | $849K | Sell |
8,714
-5,221
| -37% | -$652K | ﹤0.01% | 1904 |
|
|
2020
Q2 | $2.17M | Buy |
13,935
+3,360
| +32% | +$511K | ﹤0.01% | 1678 |
|
|
2020
Q1 | $1.53M | Buy |
10,575
+1,675
| +19% | +$323K | ﹤0.01% | 1661 |
|
|
2019
Q4 | $1.82M | Buy |
8,900
+476
| +6% | +$86.8K | ﹤0.01% | 1742 |
|
|
2019
Q3 | $676K | Buy |
8,424
+168
| +2% | +$14.3K | ﹤0.01% | 1890 |
|
|
2019
Q2 | $779K | Buy |
8,256
+937
| +13% | +$80.9K | ﹤0.01% | 1880 |
|
|
2019
Q1 | $626K | Buy |
+7,319
| New | +$608K | ﹤0.01% | 1892 |
|
|
2018
Q4 | – | Sell |
-3,069
| Closed | -$251K | – | 2329 |
|
|
2018
Q3 | $251K | Buy |
+3,069
| New | +$216K | ﹤0.01% | 2118 |
|
Other funds holding RETA
Principal Financial Group's RETA Position: Q3 2023 in Review
Principal Financial Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,051 shares — an estimated $719K sold.
Principal Financial Group first reported a position in RETA in Q3 2018 and held it in 16 quarters. The position peaked at $2.17M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Principal Financial Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Principal Financial Group sold 7,051 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $719K.
- Principal Financial Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 16 quarters.
- Principal Financial Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.17M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Principal Financial Group's 13F filing for Q3 2023, filed 2 Nov 2023.